Liver carcinoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
Survivin expression in hepatocellular carcinoma: correlation with proliferation, prognostic parameters, and outcome.
|
15195112 |
2004 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Targeting of X-linked inhibitor of apoptosis protein or survivin by short interfering RNAs sensitize hepatoma cells to TNF-related apoptosis-inducing ligand- and chemotherapeutic agent-induced cell death.
|
16211302 |
2005 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
[Effect of inhibiting survivin expression with antisense oligodeoxynucleotides on sensitivity of hepatocellular carcinoma cell lines HepG2 and HepG2/ADM to adriamycin].
|
16086872 |
2005 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
Relationship between survivin expression and recurrence, and prognosis in hepatocellular carcinoma.
|
18069771 |
2007 |
Liver carcinoma
|
0.400 |
Therapeutic
|
disease |
CTD_human |
[Effect of inhibiting survivin expression with antisense oligodeoxynucleotides on sensitivity of hepatocellular carcinoma cell lines HepG2 and HepG2/ADM to adriamycin].
|
16086872 |
2005 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Expression and significance of new inhibitor of apoptosis protein survivin in hepatocellular carcinoma.
|
15991282 |
2005 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Additionally, plasmid-based siRNA against Birc5 and/or Hspa5 were constructed and transfected into the human hepatocellular liver carcinoma cell line, HepG2.
|
22581315 |
2012 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
Survivin expression in early hepatocellular carcinoma and post-treatment with anti-cancer drug under hypoxic culture condition.
|
17879398 |
2007 |
Liver carcinoma
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Resistance to cisplatin-induced apoptosis via PI3K-dependent survivin expression in a rat hepatoma cell line.
|
20514400 |
2010 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
The effect of ursodeoxycholic acid on the survivin in thapsigargin-induced apoptosis.
|
12609713 |
2003 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Besides, genes BIRC5, CDC20, CCNB1, BUB1B, MAD2L1 and CDK1 as the hub genes might play important roles for diagnosing and therapy of HCC.
|
25753876 |
2015 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
Expression of survivin mRNA associates with apoptosis, proliferation and histologically aggressive features in hepatocellular carcinoma.
|
15547736 |
2004 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis.
|
17087938 |
2006 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, we deeply mined the integrated large-scale datasets from public microarrays and immunohistochemistry to validate the overexpression of BIRC5 and SQSTM1 while down-regulated FOXO1 expression in HCC.
|
29707114 |
2018 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Resistance to cisplatin-induced apoptosis via PI3K-dependent survivin expression in a rat hepatoma cell line.
|
20514400 |
2010 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Hepatitis B virus X protein upregulates survivin expression in hepatoma tissues.
|
16173017 |
2005 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Compared the same and different activated and inhibited BIRC5 network with GO analysis between no-tumor hepatitis/cirrhosis and HCC, our result showed BIRC5 cell cycle network weaker transcription factor activity in both no-tumor hepatitis/cirrhosis and HCC (1); stronger nucleus protein binding but weaker cytoplasm protein binding in no-tumor hepatitis/cirrhosis (2); stronger cytoplasm protein phosphatase binding but weaker ubiquitin-protein ligase activity in HCC (3).
|
21312234 |
2011 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
[Down-regulation of survivin in growth inhibition of hepatoma cells induced by a selective cyclooxygenase-2 inhibitor].
|
18815458 |
2008 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Inducible nitric oxide synthase and survivin messenger RNA expression in hepatocellular carcinoma.
|
12374680 |
2002 |
Squamous cell carcinoma
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
To investigate, whether increased copy numbers of the survivin-encoding gene BIRC5 results in elevated survivin levels and whether BIRC5 and survivin could serve as progression markers in the clinical course of OSCC, tumor tissue microarray analysis was performed applying fluorescence in situ hybridization and immunohistochemistry to 296 OSCC specimens.
|
17187360 |
2007 |
Squamous cell carcinoma
|
0.390 |
Biomarker
|
disease |
BEFREE |
Integrative Histologic and Bioinformatics Analysis of BIRC5/Survivin Expression in Oral Squamous Cell Carcinoma.
|
30205554 |
2018 |
Squamous cell carcinoma
|
0.390 |
AlteredExpression
|
disease |
LHGDN |
Cell growth inhibition and down-regulation of survivin by silibinin in a laryngeal squamous cell carcinoma cell line.
|
18998509 |
2008 |
Squamous cell carcinoma
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
Specifically, we found that BIRC5, which codes for survivin, is upregulated in both adenocarcinoma and squamous cell carcinoma tissues and that high expression of BIRC5 is associated with poor survival in adenocarcinoma, but not squamous cell carcinoma.
|
29416000 |
2018 |
Squamous cell carcinoma
|
0.390 |
Biomarker
|
disease |
CTD_human |
PIAS3, SHP2 and SOCS3 Expression patterns in Cervical Cancers: Relevance with activation and resveratrol-caused inactivation of STAT3 signaling.
|
26432044 |
2015 |
Squamous cell carcinoma
|
0.390 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the potential expression and prognostic significance of the apoptosis inhibitor survivin in squamous cell carcinoma (SCC).
|
11418003 |
2001 |